Division of Pulmonary and Critical Care Medicine, University of Maryland, Baltimore, MD, USA.
Adv Chronic Kidney Dis. 2013 Jan;20(1):30-8. doi: 10.1053/j.ackd.2012.10.007.
A growing number of guidelines and recommendations advocate a restrictive transfusion strategy. Strong evidence exists that a hemoglobin threshold of less than 7 g/dL conserves resources and may improve outcomes in critically ill patients and that platelet counts greater than 10,000/μL are well tolerated. Patients with coronary artery disease can be safely managed with a restrictive transfusion strategy, utilizing a hemoglobin threshold of less than 7 or 8 g/dL; a threshold of less than 8 g/dL can be applied to patients with acute coronary syndromes. In the absence of coagulopathy with bleeding or high risk for bleeding, plasma transfusion should be withheld. Complications from transfusion are significant and previously under-recognized immunologic complications pose a more serious threat than infections. Erythropoietin and iron administration do not reduce transfusion needs in the critically ill. Interventions to reduce blood loss and educate clinicians are successful in reducing transfusion requirements.
越来越多的指南和建议主张采用限制性输血策略。有强有力的证据表明,血红蛋白阈值低于 7 g/dL 可以节约资源,并可能改善危重症患者的预后,血小板计数大于 10,000/μL 时也能很好耐受。对于患有冠状动脉疾病的患者,可以采用限制性输血策略进行安全管理,将血红蛋白阈值设定为低于 7 或 8 g/dL;对于患有急性冠状动脉综合征的患者,可以将阈值设定为低于 8 g/dL。在没有出血或高出血风险的凝血功能障碍的情况下,应避免输注血浆。输血相关并发症很严重,以前被低估的免疫并发症比感染造成的威胁更严重。促红细胞生成素和铁剂的应用并不能减少危重症患者的输血需求。减少失血的干预措施和对临床医生的教育可以成功地降低输血需求。